robbins cv 04-04-14
TRANSCRIPT
Jeffrey Robbins, PhD
CONTACT INFORMATION Cincinnati Children’s Hospital Medical Center [email protected] Heart Institute, Molecular Cardiovascular Biology 513-‐636-‐8098 3333 Burnet Ave; MLC 2013 513-‐636-‐0100 (fax) Cincinnati, OH 45239-‐3039 Date of Birth: October 30, 1950
EDUCATION 1972 BA University of Rochester, Rochester, NY 1976 PhD University of Connecticut at Storrs, CT
ACADEMIC APPOINTMENTS 1978-‐1984 Assistant Professor, Biochemistry, University of Missouri-‐Columbia,
Columbia, MO 1984-‐1985 Associate Professor, Biochemistry, University of Missouri-‐Columbia,
Columbia, MO 1985-‐1992 Associate Professor, Pharmacology and Cell Biophysics, University of
Cincinnati College of Medicine, Cincinnati, OH 1992-‐1998 Professor, Pharmacology and Cell Biophysics, University of Cincinnati
College of Medicine, Cincinnati, OH 1993-‐ Professor, Pediatrics; Director, Molecular Cardiovascular Biology,
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 1999-‐ Associate Chair, Cincinnati Children’s Research Foundation, Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH 2008-‐ Executive Co-‐Director, Heart Institute, Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH
AWARDS AND HONORS 1968-‐1972 State of New York Regents Scholarship (Undergraduate) 1971 Atomic Energy Commission Summer Fellow 1972 Connecticut Summer Research Fellow (Graduate) 1972-‐1976 National Research Service Award Training Grant Recipient 1977-‐1978 Fellow, American Cancer Society 1981-‐1982 Chair, Mid-‐Missouri Muscular Dystrophy Scientific Council 1986 Elected to The Graduate Faculty, University of Cincinnati 1986-‐1991 Established Investigator of the American Heart Association 1990-‐1991 Golden Apple Award for medical teaching, Biochemistry/Molecular Biology 1997 Distinguished Faculty Award, University of Cincinnati 1998 Research Merit Award of the American Heart Association, Ohio-‐West Virginia
Affiliate
2
1999 Kaplan Award for Visionary Research, American Heart Association 2001 Elected Fellow of the American Heart Association 2001 Elected Fellow of the International Society for Heart Research 2005 National American Heart Association Research Achievement Award 2007 Presidential Award for Research, International Society for Heart Research 2008 Nominated for and awarded the Basic Cardiovascular Sciences Council’s
Distinguished Scientist Award, American Heart Association 2009 Elected Distinguished Fellow and University Professor of the Graduate
School, University of Cincinnati 2009 George Rieveschl Award for Distinguished Scientific Research, University of
Cincinnati 2009 The Daniel Drake Medal, University of Cincinnati 2010 Research Achievement Award, The International Society for Heart Research 2011 Fyler Visiting Professor at Harvard University 2011 Elected fellow of the International Academy of Cardiovascular Sciences 2011 Recipient of the National American Heart Association’s Basic Research Prize 2011 Chair, National Institutes of Health, Special Emphasis Panel 2012 The Executive Board, The International Society for Heart Research
MEMBERSHIPS 1979-‐present American Association for the Advancement of Science 1985-‐present American Society for Biochemistry and Molecular Biology 1998-‐present Heart Failure Society of America 1990-‐present Basic Research Council, American Heart Association 1998-‐present International Society for Heart Research 2009-‐present Executive Leadership, Basic Research Council, American Heart
Association 2011-‐present Elected to the International Academy of Cardiovascular Sciences
NATIONAL SERVICE 1980-‐1983 Ad hoc member, NIH BIOL-‐1 study section 1985-‐1988 Regular member, USDA Animal Development Study Section 1987-‐1991 Regular member, NIH BIOL-‐1 Study Section 1989-‐present Abstract reviewer, American Heart Association Scientific Sessions 1991-‐1993 Executive Board, Council for Basic Research, American Heart
Association 1991-‐1995 Regular member, NIH reviewer reserve, (called 9 times) 1992-‐1996 Regular member, American Heart Association, Grant Review Study
Section 1994-‐1998 Regular member, NIH Cardiovascular (A) Study Section 1995-‐1998 Peer Review Panel, American Heart Association Ohio Affiliate 1997-‐1998 Nominating Committee, American Heart Association 1997-‐2000 Chair, Peer Review Panel of American Heart Association Ohio Affiliate 1998 Chair, Special Emphasis Review Panel for the NHLBI
3
1997-‐2000 Chair, American Heart Association (National), Grant Review Study Section Molecular Biology of Muscle
1997-‐1999 Reviewer, Student Scholarship Program, American Heart Association 1999-‐2001 Member, Organizing Committee for Heart Failure Society of America
Annual Scientific Conference 1999 Member, Organizing Committee for International Society of Heart
Research Annual Scientific Conference 1999-‐2003 Abstract reviewer, Heart Failure Society of America national meeting 1999 NIH, Grant Review Committee Assessment Study 2000 NIH, Review of SCOR Grants 2000 Chair, American Tobacco Institute, Grant Review Study Panel 2001-‐2002 At-‐large delegate, Executive Committee, Basic Research Council,
American Heart Association 2002-‐2005 Chair of Research Council, American Heart Association, Mid-‐Ohio
Affiliate 2004-‐2008 Research Representative, Budget Oversight Committee, National
American Heart Association 2003-‐2007 Served on 7 national review panels for the National Institutes of
Health for reviewing Program Project Grants 2004-‐2007 American Heart Association Scientific Publications Committee 2003-‐2006 Louis N. and Arnold M. Katz Basic Research Prize Committee,
American Heart Association 2007-‐2009 Melvin L. Marcus Young Investigator Award Committee, American
Heart Association 2007-‐2009 Basic Cardiovascular Sciences Committee, American Heart Association 2007 Awards Committee, International College of Cardiology 2008-‐2010 Member, Nominating Committee, American Heart Association 2008-‐2010 Chair, Melvin L. Marcus Young Investigator Award Committee,
American Heart Association 2008-‐2013 Chair, National Review Committee for the Jon DeHaan Myogenesis
Program 2008-‐present Basic Cardiovascular Science Leadership Council, American Heart
Association 2009-‐2010 Member, NIH Study Panel for Mentored Transition Awards (K99/K00) 2011 Chaired or sat on 7 Special Emphasis Panels, NIH 2011 Reviewer for Welcome Trust, UK 2012 Chair, Review Special Emphasis Panel, NIH 2012 Grant review for the Spanish Government 2012 Chair, Review Panel for Young Investigator Award, Basic Council for
Cardiovascular Sciences, American Heart Association 2012-‐ Member, North American Council for the International Society for
Heart Research
4
EDITORIAL BOARDS 1991-‐1996 Journal of Biological Chemistry 1992-‐present Circulation Research 1992-‐present Trends in Cardiovascular Medicine 1995-‐present Circulation 1995-‐present Journal of Muscle Research and Cell Motility 1996-‐present Cardiovascular Engineering 1998-‐present Series Editor, Cardiovascular Molecular Morphogenesis 1999-‐2004 Associate Editor, Journal of Molecular and Cellular Cardiology 2004-‐present Journal of Molecular and Cellular Cardiology 1999-‐present Consulting Editor, Pediatric Research 2007-‐present Cooperating Editor, Cell and Tissue Research 2007-‐present Clinical and Translational Science 1999-‐2010 Cardiovascular Section Editor, Annual Reviews of Physiology 2008-‐present Journal of Molecular and Cellular Cardiology 1999-‐2004 Journal of Biological Chemistry 2000-‐2003 Current Molecular Medicine 2000-‐2005 Associate Editor, Cardiovascular Toxicology 2009-‐present Senior Associate Editor, Circulation Research
OTHER JOURNALS REQUESTING REVIEWS Journal of Clinical Investigation American Journal of Physiology Journal of Cell Biology Cardiovascular Research Journal of Molecular Biology Molecular & Cellular Biology Nature Nature Cell Biology Nature Genetics Nature Biotechnology Nature Medicine Development Science Developmental Biology Proceedings of the National Academy of Sciences, USA Cell
TRAINEES Former Students: T. Conrad Gilliam, PhD, Professor, Human Genetics; Dean for Research and Graduate
Education, Biological Sciences Division, University of Chicago James Gulick, MS, Research Instructor, Cincinnati Children’s Hospital Medical Center Greg A. Freyer, PhD, Associate Professor, Clinical Environmental Health Sciences, Columbia
University Mailman School of Public Health Thomas Horan, Research Scientist, National Plant Institute Alejandro Sánchez Alvarado, PhD, Professor, Howard Hughes Investigator, Stowers
Institute Joseph J. Palermo, MD, PhD, Assistant Professor, Cincinnati Children’s Hospital Medical
Center Stephanie Knotts, MD, PhD, Associate Professor, Cincinnati Children’s Hospital Medical
Center
5
Carmen Quatman, MD, PhD, Research Associate, The Ohio State University Shawna Hottinger, MS, Medical Writer, Cincinnati Children’s Hospital Medical Center David Terrell, University of Cincinnati Anna Valentine, University of Cincinnati Former Faculty & Fellows: Keith Kropp, Group Leader, Hoescht Om P. Srivastava, PhD, Professor, School of Optometry, University of Alabama at
Birmingham, AL Beverly Bauer, Research Scientist, Connaught Laboratories Willie A. Ng, MD, Pediatric Cardiologist, Hyde Park Pediatrics Arun Subramaniam, PhD Lead Research Investigator, Sanofi-‐Genzyme R&D Center Timothy Hewett, PhD, Director of Research, Sports Medicine, The Ohio State University Janice Parker-‐Thornburg, PhD, Associate Professor, The University of Texas MD Anderson
Cancer Center Joseph DiSalvo, Chairman, Physiology, University of Minneapolis at Deluth John McAuliffe III, MD, MBA, Associate Professor, Research Director, Cincinnati Children’s
Hospital Medical Center Hansjörg Rindt, PhD, Assistant Research Professor, Veterinary Pathobiology, University of
Missouri W. Keith Jones, PhD, Professor, Pharmacology & Cell Biophysics, University of Cincinnati Qinglin Yang, PhD, Associate Professor, Nutrition Sciences, University of Alabama at
Birmingham Xuejun Wang, MD, PhD, Professor, Biomedical Sciences, University of South Dakota Jody White, PhD, Postdoctoral Fellow, Cincinnati Children’s Hospital Medical Center Atsushi Sanbe, PhD, Associate Professor, Molecular, Cell Pharmacology, National Research
Institute for Child Health and Development, Tokyo, Japan Michael-‐Alice Moga, MD, Assistant Professor, Cardiology, Northwestern University Maike Krenz, MD, Assistant Professor, Medical Pharmacology and Physiology, University of
Missouri Jeanne James, MD, Associate Professor, Cincinnati Children’s Hospital Medical Center Tomoki Nakamura, MD, Associate Professor, Kyoto Hospital, Japan Sakthivel Sadayappan, PhD, Assistant Professor, Cell & Molecular Physiology, Loyola
University Alina Maloyan, PhD, Assistant Professor, University of Texas Health Science Center, San
Antonio J. Scott Pattison, PhD, Assistant Professor, University of South Dakota Sudarsan Rajan, PhD, Research Instructor, Temple University Md. Abdur Razzaque, PhD, Associate Scientist, University of Wisconsin, Madison School of
Medicine & Public Health Current Trainees: Patrick McLendon, PhD Md. Shenuarin Bhuiyan, PhD Manish Gupta, PhD
6
INVITED LECTURES 1995 “Transgenic analyses of cardiac gene expression” Department of Medicine, Baylor
College of Medicine, Houston, TX 1995 “Combinatorial events and muscle gene expression” Department of Cell Biology and
Anatomy, State University of New York, Syracuse, NY 1995 “The chemistry of transcription” Department of Chemistry, Xavier University of
Louisiana, New Orleans, LA 1995 “Molecular Basis of Congenital Heart Disease” Organizing Committee, American
Heart Association, New Orleans, LA 1995 “Transgenic approaches to understanding light chain function” American Heart
Association Conference, New Orleans, LA 1995 “The myosin knockout” Organizing Committee, Session Chair and Speaker, NIH
Conference on Mouse Models of Disease, Bethesda, MD 1995 “Transgenic models of human heart disease” Organizing Committee, Session
Chair and Speaker, NIH Conference on Morphogenesis of the Heart, Rochester, NY 1995 “The myosin light chains and cardiac function” Session Chair and Speaker, Impact
of Molecular Biology on Cardiovascular Disease, State University of New York, Downstate Medical Center, Brooklyn, NY
1995 “Remodeling the heart through transgenesis” Division of Molecular Cardiovascular Biology, Genentech, San Francisco, CA
1995 “The transgenic mouse as a model for cardiovascular disease” The Gladstone Institutes, San Francisco, CA
1995 “Transgenic analyses of cardiac gene expression” Bristol-‐Meyer Squibb Symposia on Cardiovascular Animal Models, University of Minnesota, Minneapolis, MN
1995 “Myosin function and structure” Department of Medicine, Cleveland Clinic, Cleveland, OH
1995 “Cardiovascular molecular development” Session Chair and Moderator, American Heart Association, Scientific Sessions, Anaheim, CA
1995 “Transcriptional and post-‐transcriptional regulation of the contractile proteins” Department of Molecular Physiology, University of Vermont, Burlington, VT
1995 “Transgenic approaches for modifying the heart” Section of Cardiovascular Medicine, Yale University, New Haven, CT
1995 “Gene targeting of the cardiac myosin genes” Department of Physiology, Yale University, New Haven, CT
1996 “Contractile protein stoichiometry and cardiac dysfunction” Symposium of Fundamental Heart Research, Yale University, College of Medicine, New Haven, CT
1996 “Molecular biological approaches to understanding cardiac physiology” Baylor College of Medicine, Houston, TX
1996 “Post-‐transcriptional controls for the muscle proteins” Speaker, Session Chair and Moderator, Keystone Symposium, The Molecular Biology of the Cardiovascular System, Snowbird, UT
1996 “Genetic approaches to physiology: from the gene to whole organ function” Department of Physiology, University of Madison-‐Wisconsin, Madison, WI
1996 “Transgenic models of muscle function” Tutorial Lecture, National Meeting, American College of Sports Medicine, Cincinnati, OH
7
1996 “Gene transfer and muscle structure” Plenary Lecture, National Meeting, American College of Sports Medicine, Cincinnati, OH
1996 “Transgenesis and gene targeting of the myosins” Research Lecture, National Meeting, American College of Sports Medicine, Cincinnati OH
1996 “Gene replacement of myosin light chains and cardiac dysfunction in the transgenic heart” American Heart Association’s Molecular Biology of the Normal, Hypertrophied and Failing Heart, Snowbird Symposium, Snowbird, UT
1997 “Protein remodeling of the mammalian heart” University of Washington, Seattle, WA
1997 “The myosin gene family” State University of New York, Downstate Medical Center, Brooklyn, NY
1997 “Transgenic approaches for understanding heart function” University of Pennsylvania, Philadelphia, PA
1997 “Transgenesis and gene targeting of contractile protein genes” Adult Cardiology, University of Cincinnati, Cincinnati, OH
1997 “Myosin light chains: structure-‐function relationships” Keystone Symposium, Snowmass, UT
1997 “Modification of cardiac muscle by molecular genetic approaches” University of Colorado, Denver, CO
1997 “Cardiac physiology in the mouse” Albert Einstein College of Medicine, New York, NY
1997 Meeting Organizer, Weinstein Cardiovascular Conference, “Cardiogenesis and Development,” Cincinnati, OH
1997 “Transgenesis and heart function” ISHR World Congress, St. Petersburg, Russia 1997 “Remodeling the heart using transgenesis and gene targeting” Rachford Lecture,
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 1997 “Molecular biology and physiology of the mouse heart” McGill University, Montreal,
QB Canada 1997 “Cardiac function in transgenic mice” University of Texas, San Antonio, TX 1997 “Molecular physiology of the mouse” University of Cincinnati, OH 1997 “Heart development and morphogenesis” Chair, American Heart Association
Scientific Sessions, Orlando, FL 1997 “From molecular genetics to heart physiology” Molecular Approaches to
Cardiovascular Development, Merck-‐Frost, Montreal, QB, Canada 1997 “Cardiovascular Models” Pfizer Lecture (Teleconference) Osaka, Japan 1998 “Remodeling the heart using transgenic approaches” Washington University, St.
Louis, MO 1998 “Models of congestive heart failure” Keynote Speaker and Session Chair,
Circulation Meeting, Tokyo, Japan 1998 “Frontiers of cardiovascular research” Rosenthal Memorial Lecture, University of
Michigan, Ann Arbor, MI 1998 “Hypertrophic cardiomyopathic models” Keynote Speaker and Session Chair,
ISHR World Congress, Rhodes, Greece 1998 “Producing FHC in mice: what multiple models tell us” University South Carolina,
Columbia, SC
8
1998 “Animal models of cardiac disease” Massachusetts General Hospital, Harvard University, Boston, MA
1998 “Achieving high levels of muscle-‐specific gene expression in vivo” CSH Workshop, Muscle Gene Regulation and its Therapeutic Potential
1998 “Lectures on cardiovascular development and function” Mead-‐Johnson Workshop, Congenital Heart Disease, Aspen, CO
1998 “Making mouse models of cardiovascular disease: the transgenic paradigm” Millennium Corporation
1998 “A mouse model of familial hypertrophic cardiomyopathy” Session Chair and Speaker, American Heart Association Scientific Sessions, Dallas, TX
1998 “Structure-‐function relationships of contractile proteins: the in vivo approach” Hospital for Sick Children, Toronto, ON, Canada
1998 “Genetic approaches to biochemical problems: cardiac function” Vanderbilt University, Nashville, TN
1999 “Cardiovascular gene therapy” Distinguished Scientist Lecture, State University of New York, Downstate Medical Center, Brooklyn, NY
1999 “Secrets of the sarcomere” Federation of American Societies for Experimental Biology, Washington, DC
1999 “Genetic models of heart failure” University of California, San Diego, CA 1999 “Structure-‐function studies of contractile proteins using transgenesis” Gordon
Conferences, Colby-‐Sawyer College, NH 1999 “Transgenic models of heart disease” International Fetal Physiology Symposium,
Aspen, CO 1999 “Transgenic models of human cardiovascular disease” The Ohio State University,
Biotechnology Center, Columbus, OH 1999 “Remodeling the cardiac contractile apparatus” International Symposium of Heart
Failure, San Francisco, CA 1999 “Affecting cardiac function” American Heart Association Special Symposium,
Cellular and Integrated Physiological Approaches to the Failing Heart, Aspen, CO 1999 “Cardiomyopathies” American Heart Association Scientific Sessions, Sunday
morning program, What In Vivo Engineering has Taught Us, Atlanta, GA 1999 “Transgenic remodeling of the myocardium” Cor Therapeutics, San Francisco, CA 1999 “Control of the cardiomyocyte” NIH Workshop, Thrombogenicity, Bethesda, MD 1999 “The cardiac contractile apparatus” Case Western Reserve University, Cleveland, OH 1999 “Structure-‐function studies of cardiac contraction” Berlin University, Berlin,
Germany 1999 “Gene therapy in the cardiovascular system” State University of New York,
Downstate Medical Center, Brooklyn, NY 2000 “Transgenic approaches to studying early mammalian development” Loma Linda
University, Loma Linda, CA 2000 “Structure-‐function studies of cardiovascular pathogenesis” Keystone Symposium,
Keystone, CO 2000 “The underlying mechanisms of heart failure” The Leonard Leight Distinguished
Lectureship, University of Louisville, College of Medicine, Louisville, KY 2000 “The desmin-‐related cardiomyopathies” George Washington School of Medicine,
9
Washington, DC 2000 “Transgenic approaches to cardiovascular disease” Keynote Speaker, Third
International Symposium on Cardiomyocytes in Culture, Centro Stefano Franscini, Monte Verità, Ascona, Switzerland
2000 “Transgenic approaches to myofibrillar function” Gordon Conferences, Cardiac Regulatory Mechanisms, Colby-‐Sawyer College, NH
2000 “Modern approaches to cardiovascular toxicology” Society of Toxicology National Meeting, Philadelphia, PA
2000 “Transgenic approaches and heart failure” Heart Failure Summit 2000, Toronto, ON, Canada
2000 “Intermediate filaments and heart disease” International Society for Heart Research, Louisville, KY
2000 “Structure-‐function relationships underlying hypertrophy and failure” Society of Heart Failure, Boca Raton, FL
2000 “Hypertrophy and failure” American Heart Association Scientific Sessions, New Orleans, LA
2000 “Physiology and transgenesis in cardiovascular research” Federation of American Societies for Experimental Biology, San Diego, CA
2000 “Myocardial function and the contractile apparatus” Johns Hopkins University, Baltimore, MD
2000 “Pathogenic processes underlying hypertrophy” American Physiological Society National Meeting, Portland, OR
2000 “Grand Rounds” Brigham and Women’s Hospital, Harvard University, Boston, MA 2000 “Myosin isoforms and their function” University of Vermont, Burlington, VT 2001 “Transgenic remodeling of contraction” Baylor College of Medicine, Houston, TX 2001 “Cardiac structure and function” State University of New York, Downstate Medical
Center, Brooklyn, NY 2001 “Transgenic approaches to cardiovascular physiology” Symposium, Cardiac
Function – Osaka 2001: Topics in Genomics, Proteomics, and Physiomics, Osaka, Japan 2001 “Intermediate filaments and hypertrophic signaling” Japanese Society for
Circulation, Kyoto, Japan 2001 “Cardiac gene therapy” State University of New York, Downstate Medical Center,
Brooklyn, NY 2001 “The contractile proteins: structure, function and physiology” The Canadian
Physiological Society, Montreal, QB, Canada 2001 “Structure-‐function studies of the cardiac contractile proteins” Baylor College of
Medicine, Houston, TX 2001 “Physiological correlates of cardiac isoforms” University of Texas Southwestern,
Dallas, TX 2001 “Fellows’ Choice Distinguished Faculty” Pediatric Cardiology, University of
Michigan, Ann Arbor, MI 2001 “The Desminopathies” AHA Scientific Sessions, Anaheim, CA 2001 “Transgenic Studies in Heart Failure” University of South Dakota, College of
Medicine, Vermillion, SD 2001 “Transgenic Approaches to Studying Cardiovascular Disease” Keynote Speaker,
10
ISHR Satellite Conference, Burlington, VT 2001 “Cytoskeletal Abnormalities in Cardiovascular Disease” ISHR Meeting, Winnipeg,
MB, Canada 2002 “Transgenic remodeling of contraction” Morehouse University, Atlanta, GA 2002 “Structure-‐function studies of cardiac myosin” Case Western Reserve University,
Cleveland, OH 2002 “Transgenic approaches for understanding myosin in the heart” Session Chair and
Speaker, Gordon Conference 2002 “Genomics and cardiac failure” Keynote Speaker, Third Annual Molecular Imaging
Workshop: Cardiovascular and Beyond, University of Michigan, Ann Arbor, MI 2002 “Animal models of cardiac hypertrophy” NIH Workshop, Washington, DC 2002 “Cardiac failure: a genetic approach” Featured Lecture, XXIV ISHR Meeting,
Madison, WI 2002 “Cardiac failure: how not to fail” Keynote Speaker, Gordon Conference, Cardiac
Function, Connecticut College, New London, CT 2002 “Cardiac Research: the future” The Kaplan Lectureship, Children’s Hospital,
Cincinnati, OH 2002 “The desmin-‐ and crystallinopathies” Session Chair and Speaker, AHA Heart
Failure Meeting, Snowbird, CO 2002 “Pathways in hypertrophy” Session Chair and Speaker, AHA Heart Failure
Meeting, Snowbird, CO 2002 “Transgenic approaches for understanding cardiovascular abnormalities” Keynote
Speaker, The New England Conference on Perinatal Research, Cape Cod, MA 2002 “Genetics and the heart: a functional approach” at Brown University, Providence, RI 2003 “Myosin substitutions: structure-‐function of contraction” Duke University, Durham,
NC 2003 “Structure-‐function studies of cardiac myosin” Harvard Medical School, Boston, MA 2003 “The Astra-‐Zeneca Master’s Lecture” Harvard University, Boston, MA 2003 “Genomics and heart failure” University of South Dakota, Vermillion, SD 2003 “Animal models of cardiac hypertrophy” Featured Lecture, XXV ISHR Meeting, CT 2003 “Cardiac failure and the desminopathies” AHA Conference, Heart Failure and
Signaling Pathways, Snowbird, CO 2003 “Cardiac Research: the future” The Kaplan Lectureship, Cincinnati Children’s
Hospital Medical Center, Cincinnati, OH 2003 “Structure-‐function relationships of the contractile proteins” The Gordon
Conferences, Sawyer-‐Colby College, New London, NH 2003 “Transgenic approaches to understanding heart disease” Federation of American
Societies for Experimental Biology Meeting, San Diego, CA 2003 “Masters series in cardiovascular disease” The University of Ottawa, Ottawa, ON,
Canada 2003 “The desmin-‐ and crystallinopathies” Session Chair and Speaker, AHA Heart
Failure Meetings, Snowbird, CO 2003 “DRM and cardiovascular disease” American Heart Association Scientific Sessions,
Orlando, FL 2004 “The stress response and heart failure” The Whitaker Cardiovascular Institute
11
Series, Boston University, Boston, MA 2004 “Desmin related myopathies: Alzheimer’s of the heart?” Cleveland Clinic, Cleveland,
OH 2004 “Proteomic approaches to cardiovascular disease” University of California, Los
Angeles, Los Angeles, CA 2004 “Desmin-‐related cardiomyopathies: form and function” Session Chair, Keystone
Symposia, Heart Failure and Disease, Keystone, CO 2004 “Myosin substitution via transgenesis in rabbits” Myogen, Inc., Denver, CO 2004 “Intermediate Filaments, chaperones and heart failure” Session Chair, Cell and
Gene Therapy Conference, Boston, MA 2004 “Convergence of signaling pathways at the contractile apparatus” COBRA Research
Conference, Yellowstone National Park, WY 2004 “Discussion Leader” Gordon Research Conference, Cardiac Regulatory Mechanisms,
Colby-‐Sawyer College, New London, NH 2004 “Stress response and heart failure” Session Chair, 1st Annual Basic Sciences
American Heart Association Symposium, Stevenson, WA 2004 “Plenary Session Talk” The Australian Health & Medical Research Conference,
Sydney, Australia 2004 “Creating animal models of human cardiovascular disease” The Edwards Oration
Lecture, The Australian Health & Medical Research Conference, Sydney, Australia 2004 “Analyses of cardiovascular disease models” American Heart Association Scientific
Sessions, New Orleans, LA 2004 “The desmin related cardiomyopathies and their relationships to
neurodegenerative disease” Wright State University, Dayton, OH 2004 “When good proteins go bad: the unfolding story” Branbury Lecture, Cold Spring
Harbor Laboratory, Cold Spring Harbor, NY 2004 “The desmin related cardiomyopathies and 11myloidosis” Grand Rounds,
Northwestern University College of Medicine, Chicago, IL 2004 “Heart failure and the unfolded protein response” Cardiovascular Frontier Lecture,
Boehringer Ingelheim Research, Danbury, CT 2004 “Cardiovascular transgenesis” COBRE Lecture, Yellowstone Conference, MT 2004 “Frontiers in Cardiovascular Science” Wright State University, Dayton, OH 2005 “Dilated Cardiomyopathy and Amyloids – an unfolding story” The Ohio State
University, Columbus, OH 2005 “Novel cardiovascular disease pathways and the unfolded protein response”
Keynote Speaker, 5th Annual Symposium of Cardiovascular Development, Charleston, SC
2005 “Desmin-‐related cardiomyopathies: form and function” Gordon Research Conference, Newport, RI
2005 “Aggresomes and heart disease” Grand Rounds, Mount Sinai Medical Center, New York, NY
2005 “The unfolded protein response and heart disease” American Heart Association Scientific Sessions, Dallas, TX
2005 “New links between the neurodegenerative diseases and heart failure: an unfolding story” Crosstalk Series, Cincinnati Children’s Hospital Medical Center, Cincinnati,
12
OH 2005 “Changing the outcome in human heart failure; myosin isoform switching in a
transgenic rabbit model” American Society for Molecular Biology National Meeting, San Francisco, CA
2005 “Stem cells and potential therapies for cardiovascular disease” State University of New York, Downstate Medical Center, Brooklyn, NY
2006 “Links between neurodegenerative disease and cardiovascular molecular biology” The COBRE Seminar, Brown University, Providence RI
2006 “Unfolded proteins and cardiovascular disease” University of Cincinnati, The Lingrel Symposium, Cincinnati, OH
2006 “Cardiomyopathy: Alzheimer’s of the heart?” Division of Cardiology, Albert Einstein College of Medicine, Bronx, NY
2006 “Aggresomes and heart disease” Grand Rounds, Mount Sinai Medical Center, New York, NY
2006 “Changing the animal heart; techniques and issues” National Conference for American Association of Veterinarians, Louisville, KY
2006 “Looking into the future: how molecular genetics will change outcomes” National Conference for American Association of Veterinarians. Louisville, KY
2006 “The Role of pre-‐amyloid oligomer in cardiovascular disease” International Society for Heart Research, Toronto, ON, Canada
2006 “New links between the neurodegenerative diseases and heart failure: an unfolding story” COBRE meeting, University of South Dakota, Vermillion, SD
2006 “Cardiac regulatory mechanisms” Gordon Research Conference, Colby-‐Sawyer College, New London, NH
2006 “Cardiac protein phosphorylation and heart failure” American Heart Association Scientific Sessions
2006 “Parallel paths in the neurodegenerative diseases and heart failure” Department of Neurobiology, Montefiore Medical Center, New York, NY
2007 “The role of post-‐translational phosphorylation of contractile proteins in cardiac function” University of Vermont, Burlington, VT
2007 “Erk1/2 activity in Noonan’s syndrome” Weinstein Cardiovascular Conference, Indianapolis, IN
2007 “The Presidential Lecture” International Society for Heart Research World Congress, Bologna, Italy
2007 “The role of pre-‐amyloid oligomers in heart disease” International Society for Heart Research World Congress, Bologna, Italy
2007 “Amyloidoses and the cardiovascular system” World Congress of Cardiovascular Disease, Vancouver, BC, Canada
2007 “Enabling technologies for studying the heart,” Student’s Choice Seminar for 2007, University of Hamburg, Hamburg, Germany
2007 “The emerging role of protein phosphatases for cardiovascular and craniofacial development” University of Wurzburg, Wurzburg, Germany
2007 “Aggresomes and their roles in cardiovascular disease” American Heart Association Scientific Sessions, Orlando, FL
2007 “The death of transcriptional chauvinism in the control of cardiac contractility” 5th
13
Larry and Horti Fairberg Workshop in Biological Paradigm Change, Antalya, Turkey 2008 “Cardiomyocyte death and the accumulation of pre-‐amyloid oligomers during heart
disease and failure” Keystone Symposium, Pathological and Physiological Regulation of Hypertrophy, Copper Mountain, CO
2008 “A novel role for pre-‐amyloid oligomer pathogenesis during heart failure” Grand Rounds, Department of Medicine, Vanderbilt University, Nashville, TN
2008 “Noonan’s: birth of a syndrome” Student-‐Selected Speaker, Cardiovascular Center, Vanderbilt University, Nashville, TN
2008 “Phosphatase activity and heart disease” Cardiovascular and Cell Gene Therapy Conference IV, Mount Sinai, NY
2008 “The Wassenberg Lecture” University of California, San Diego, San Diego, CA 2008 “Molecular Basis for congenital abnormalities in Noonan’s syndrome” Scientific
Basis for Heart Failure in Children, Estes Park, CO 2008 “Desmin-‐related cardiomyopathy” American Heart Association Basic
Cardiovascular Sciences Council, Heart Failure: Molecular Mechanisms and Therapeutic Targets, Keystone Symposium, Keystone, CO
2008 “Protein Misfolding in the heart” American Heart Association Basic Cardiovascular Sciences Council, Heart Failure: Molecular Mechanisms and Therapeutic Targets, Keystone Symposium, Keystone, CO
2008 “Pre-‐amyloid oligomers in the myocardium” 14th World Congress on Heart Disease, Toronto, ON, Canada
2008 “Protein conformation disease in the heart” Sunday morning conferences, American Heart Association Scientific Sessions, New Orleans, LA
2009 “Links between the heart and mind: an unfolding story” Physiology Department, University of Cincinnati College of Medicine, Cincinnati, OH
2009 “MyBP-‐C phosphorylation and heart failure” Keystone Symposium, Common Mechanisms in Arrhythmias and Heart Failure, Keystone, CO
2009 “Commonalities between heart failure and neurodegeneration: an unfolding story” Anglers Symposium, University of California, San Diego, San Diego, CA
2009 “Contractile proteins and cardiac disease” The Sam Seidman Biophysical Workshop, Technion University, Israel
2009 “Signaling and the birth of complex congenital syndromes” 6th International Ascona Workshop on Cardiomyocyte Cell Biology, Ascona, Switzerland
2009 “The sarcomere and post-‐translational control of contraction” International Society for Heart Research North American Meeting, Baltimore, MD
2009 “Commonalities in cardiac and neural disease” Nanjing Heart Symposium, Nanjing, China
2009 “Complex syndromes and heart failure” Keynote Lecture, The Toronto Symposium on Heart Failure and Transplantation, Toronto, ON, Canada
2009 “Intracellular chaos in the failing cardiomyocyte” Heart Failure Society of America, Boston, MA
2009 “Cardiac-‐specific transgenesis: what it can and cannot do” Heart Failure Society of America, Boston, MA
2009 “Protein misfolding and cardiac disease” Keynote Lecture, The Gill Symposium, University of Kentucky, Louisville, KY
14
2009 “Protein conformation and cardiac disease” Riley Medical Center, Indiana University, Indianapolis, IN
2009 “Pre-‐amyloidoses and heart disease” American Heart Association Scientific Sessions, Orlando, FL
2010 “Cardiovascular disease and neurodegenerative disease: an unfolding story” The Texas Heart Institute, Baylor University, Houston, TX
2010 “Links between cardiovascular disease and neural disease: novel connections” University of Minnesota, Minneapolis, MN
2010 “Commonalities between heart failure and neurodegeneration” University of Edmonton, Edmonton, AB, Canada
2010 “Contractile proteins and cardiac disease: Beyond the Sarcomere” Keynote Address, International Society for Heart Research World Congress, Kyoto, Japan
2010 “Pre-‐amyloid oligomers and the desminopathies” International Society for Heart Research World Congress, Kyoto, Japan
2010 “The sarcomere and post-‐translational control” Gordon Research Conference, Calcium and Signaling, Colby-‐Sawyer College, New London, NH
2010 “Amyloidoses in heart failure” American Heart Association, Council on Basic Cardiovascular Research, Palm Springs, CA
2010 “Myosin-‐binding protein C and cardiac contractility” Heart Failure Society of America, San Diego, CA
2010 “Contractile proteins and human heart disease” Brown University, Providence, RI 2010 “Therapeutic targets in the contractile apparatus” Leducq Transatlantic Network
meeting, Zürich, Switzerland 2011 “Cardiovascular disease and neurodegenerative disease: proteotoxicity” Keystone
Symposia, Keystone, CO 2011 “Myosin-‐binding protein C and HCM” University of Vermont, Burlington, VT 2011 “Heart failure and post-‐translational controls” Loyola University, Chicago, IL 2011 “Contractile proteins and cardiac disease: Beyond the Sarcomere” The Fyler Grand
Rounds, Harvard University, Boston, MA 2011 “Pre-‐amyloid oligomers and the desminopathies” University of Rochester,
Rochester, NY 2011 “Proteotoxicity and heart failure” International Society of Heart Failure,
Philadelphia, PA 2011 “Amyloidoses in heart failure” 1st Ubiquitin, Quality Control and Molecular
Pathogenesis Symposium, University of South Dakota College of Medicine, Vermillion, SD
2011 “Myosin-‐binding protein C and cardiac contractility” American Heart Association Council on Basic Cardiovascular Science, New Orleans, LA
2011 “Myosin-‐binding protein C in cardiac disease” Institute for Molecular Medicine, Peking National University, Beijing, China
2011 “Protein toxicity and heart disease: an underappreciated pathology” International Heart Forum, Beijing, China
2011 “Contractile proteins and human heart disease” Heart Failure Society of America, Boston, MA
2011 “Redox potentials and heart disease” American Heart Association Scientific
15
Sessions, Orlando, FL 2011 “Protein Conformation based disease and heart function” Long Island University,
Brookville, NY 2012 “Heart disease and protein toxicity” Keynote Speaker, Symposium on Cardiovascular
Sciences, University of North Carolina at Chapel Hill, College Hill, NC 2012 “Pre-‐amyloid oligomer toxicity in heart failure” Molecular Genetics, Biochemistry
and Microbiology, University of Cincinnati, Cincinnati, OH 2012 “Proteotoxicity” Distinguished Lecturer, Fundación Centro Nacional de
Investigaciones Cardiovasculare, Madrid, Spain 2012 “Heart failure and amyloids” Special Lecture, Leducq Foundation Meeting,
Philadelphia, PA 2012 “Pre-‐amyloid oligomers and cardiac muscle disease” Hospital for Sick Kids, Toronto,
ON, Canada 2012 “Amyloidoses in heart failure: how do we translate what we’ve learned at the
bench?” Grand Rounds for Translational Group, University of Toronto, Toronto, ON, Canada
2012 “Proteotoxicity and heart failure ” International Leducq Network, Padua, Italy 2012 “Myosin-‐binding protein C” International Society for Heart Research, Banff, AB,
Canada 2012 “Myosin-‐binding protein C in cardiac disease” Gordon Research Conference, Cardiac
Regulatory Mechanisms, Colby-‐Sawyer College, New London, NH 2012 “Heart failure and neurodegenerative disease: common pathways?” University
Medical Center Hamburg-‐Eppendorf, Hamburg, Germany 2012 “Myosin-‐binding protein C and cardiomyopathy” Kings College, London, UK 2012 “Basic science and the cardiac intensive care unit: why should we care?” Keynote
Address, The Pediatric Intensive Care Society National Meetings, Miami, FL 2012 “Proteotoxicity and Cardiac Disease: An Unfolding Story” Brigham & Women’s
Hospital, Harvard Medical School, Boston, MA 2012 “Stem cells, iPS and heart disease; ongoing initiatives” Midwest Symposium on New
Concepts for Tissue-‐Specific Regenerative Medicine, Cincinnati, OH 2012 “Sarcomere Protein Quality Control and Aggregation in Cardiomyopathy” American
Heart Association Scientific Sessions, Los Angeles, CA 2012 “Myosin-‐binding protein C: from the bench to the bedside?” Grand Rounds, Heart
Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 2013 “Proteotoxicity and Heart” Leducq Network, Cincinnati, OH 2013 “Proteotoxicity: an unappreciated mechanism of heart disease and its potential for
novel therapeutics” International Leducq Foundation Network, Nice, France 2013 “Phosphorylation, protein fragments and structure-‐function” University of Vermont,
Burlington, VT 2013 “Proteotoxicity: an under-‐appreciated factor in heart disease” Stanford University,
Stanford, CA 2013 “Proteoxicity, aggresomes and cardiac disease” Beth Israel Deaconess Medical
Center, Boston, MA 2013 “Cardioprotection by myosin-‐binding protein C” International Society for Heart
Research World Congress, San Diego, CA
16
2013 “Protein Quality Control in the Pathogenesis Of Cardiomyopathy” Heart Failure Society of America, Orlando, FL
2013 “Preamyloids and protein quality control in the heart” American Heart Association Scientific Sessions, Dallas, TX
2014 “Program Project Grant: Myosin-‐Binding Protein C” University of Vermont, Burlington, VT
2014 “Cardiomyopathies: bridging the gap between clinic and pre-‐clinic” The Royal Netherlands Academy of Arts & Sciences Colloquium, Amsterdam, Netherlands
2014 “Heart Failure and Proteotoxicity: A Degrading Experience” Distinguished Cardiovascular Lectureship, University of California, Los Angeles, Los Angeles, CA
2014 “Autophagy and cardiac disease: cause or effect?” Experimental Biology Conference, San Diego, CA
2014 “Myosin-‐binding protein C: structure and function” International Society for Heart Research, Miami, FL
2014 “Transformational Science: How to Do It” Gordon Research Seminar, Cardiac Regulatory Mechanisms, Colby-‐Sawyer College, New London, NH
2014 “Proteotoxicity and Cardiac Dysfunction” American Heart Association, Council on Basic Cardiovascular Research, Las Vegas, NV
2014 “An Endogenously Produced Fragment of Cardiac Myosin-‐Binding Protein C is Pathogenic and Can Lead to Heart Failure” American Heart Association, Scientific Sessions, Chicago, IL
2014 “Cardiac Proteinopathy” American Heart Association, Scientific Sessions, Chicago, IL
17
CURRENT GRANT SUPPORT 2P01 HL69779 (Robbins: PI) 09/01/13–05/31/18 NIH/NHLBI Cardiac Signaling in the Normal and Abnormal Heart This is a program grant (1.7 million/year) within the Division of Molecular Cardiovascular Biology. Goals of Robbins’ component are to study the formation and role that pre-‐amyloid oligomers play in the development of cardiovascular disease using transgenic mouse models. 2P01 HL059408-‐07 Warshaw (PI), Robbins (Component 4 and Core C) NIH/NHLBI 2/1/00–11/30/14 Molecular Exploration of Myosin-‐Binding Protein C The major goals are to investigate how myosin’s molecular structure contributes to its enzymatic and mechanical function and how it translates into the mechanical performance of the myocardium. Leducq Transatlantic Alliance For Cardiovascular Disease 2011–2016 Jeffrey Robbins, North American Coordinator Proteotoxicity: an underappreciated factor in cardiac disease 1R01 HL105924-‐01 (Robbins Co-‐PI with Jeffery Molkentin) 01/01/11–12/31/14 NIH/NHLBI Thrombospondin 4 Regulates Adaptive ER Stress Response The major goals of this grant are to explore how thrombospondins function in the ER stress response using our model of chaperone-‐compromised heart disease. 1R01 HL1062927-‐01 (Robbins Co-‐PI with Jeffery Molkentin) 01/01/09–12/31/14 NIH/NHLBI Cardiac hypertrophy intracellular signaling pathways The major goals of this grant are to explore which pathways are necessary and sufficient in mediating hypertrophy using our model of chaperone-‐compromised heart disease.
18
PUBLICATIONS 1. Robbins J, Heywood SM. Preparation and characterization of myosin copy DNA.
Biochem Biophys Res Commun. 1976;68:918-‐926 2. Robbins J, Heywood SM. Quantification of myosin heavy-‐chain mRNA during
myogenesis. Eur J Biochem. 1978;82:601-‐608 3. Robbins J, Rosteck P, Jr., Haynes JR, Freyer G, Cleary ML, Kalter HD, Smith K, Lingrel
JB. The isolation and partial characterization of recombinant DNA containing genomic globin sequences from the goat. J Biol Chem. 1979;254:6187-‐6195
4. Parisi JT, Robbins J, Lampson BC, Hecht DW. Characterization of a macrolide, lincosamide, and streptogramin resistance plasmid in staphylococcus epidermidis. J Bacteriol. 1981;148:559-‐564
5. Robbins J, Freyer GA, Chisholm D, Gilliam TC. Isolation of multiple genomic sequences coding for chicken myosin heavy chain protein. J Biol Chem. 1982;257:549-‐556
6. Freyer GA, Robbins J. The analysis of a chicken myosin heavy chain cDNA clone. J Biol Chem. 1983;258:7149-‐7154
7. Taylor MA, McIntosh MA, Robbins J, Wise KS. Cloned genomic DNA sequences from mycoplasma hyorhinis encoding antigens expressed in escherichia coli. Proc Natl Acad Sci U S A. 1983;80:4154-‐4158
8. Gulick J, Kropp K, Robbins J. The structure of two fast-‐white myosin heavy chain promoters. A comparative study. J Biol Chem. 1985;260:14513-‐14520
9. Robbins J, Kropp K, Gulick J, Valente N. Sequence organization of the myosin heavy chain genes. Roche-‐UCLA Symposium. 1985;29
10. Kropp K, Gulick J, Robbins J. A canonical sequence organization at the 5'-‐end of the myosin heavy chain genes. J Biol Chem. 1986;261:6613-‐6618
11. Robbins J, Horan T, Gulick J, Kropp K. The chicken myosin heavy chain family. J Biol Chem. 1986;261:6606-‐6612
12. Gulick J, Kropp K, Robbins J. The developmentally regulated expression of two linked myosin heavy-‐chain genes. Eur J Biochem. 1987;169:79-‐84
13. Kropp KE, Gulick J, Robbins J. Structural and transcriptional analysis of a chicken myosin heavy chain gene subset. J Biol Chem. 1987;262:16536-‐16545
14. Molina MI, Kropp KE, Gulick J, Robbins J. The sequence of an embryonic myosin heavy chain gene and isolation of its corresponding cDNA. J Biol Chem. 1987;262:6478-‐6488
15. Robbins J, Subramaniam A, Gulick J. A multipurpose vector for the study of transcriptional control. Gene. 1989;85:541-‐544
16. de Silva HV, Harmony JA, Stuart WD, Gil CM, Robbins J. Apolipoprotein j: Structure and tissue distribution. Biochemistry. 1990;29:5380-‐5389
17. Robbins J, Gulick J, Sanchez A, Howles P, Doetschman T. Mouse embryonic stem cells express the cardiac myosin heavy chain genes during development in vitro. J Biol Chem. 1990;265:11905-‐11909
18. Subramaniam A, Gulick J, Robbins J. Analysis of the upstream regulatory region of a chicken skeletal myosin heavy chain gene. J Biol Chem. 1990;265:13986-‐13994
19. Gulick J, Subramaniam A, Neumann J, Robbins J. Isolation and characterization of the mouse cardiac myosin heavy chain genes. J Biol Chem. 1991;266:9180-‐9185
20. McAuliffe JJ, Robbins J. Troponin T expression in normal and pressure-‐loaded fetal
19
sheep heart. Pediatr Res. 1991;29:580-‐585 21. Ng WA, Grupp IL, Subramaniam A, Robbins J. Cardiac myosin heavy chain mRNA
expression and myocardial function in the mouse heart. Circ Res. 1991;68:1742-‐1750
22. Sanchez A, Jones WK, Gulick J, Doetschman T, Robbins J. Myosin heavy chain gene expression in mouse embryoid bodies. An in vitro developmental study. J Biol Chem. 1991;266:22419-‐22426
23. Subramaniam A, Jones WK, Gulick J, Wert S, Neumann J, Robbins J. Tissue-‐specific regulation of the alpha-‐myosin heavy chain gene promoter in transgenic mice. J Biol Chem. 1991;266:24613-‐24620
24. Walsh RA, Henkel R, Robbins J. Cardiac myosin heavy and light chain gene expression in hypertrophy and heart failure. Heart Failure. 1991;6:238-‐243
25. Parker-‐Thornburg J, Bauer B, Palermo J, Robbins J. Structural and developmental analysis of two linked myosin heavy chain genes. Dev Biol. 1992;150:99-‐107
26. Robbins J, Doetschman T, Jones WK, Sanchez A. Embryonic stem cells as a model for cardiogenesis. Trends Cardiovasc Med. 1992;2:44-‐50
27. Adolph EA, Subramaniam A, Cserjesi P, Olson EN, Robbins J. Role of myocyte-‐specific enhancer-‐binding factor (MEF-‐2) in transcriptional regulation of the alpha-‐cardiac myosin heavy chain gene. J Biol Chem. 1993;268:5349-‐5352
28. Dominguez-‐Steglich M, Robbins J, Schmid M. Mapping of the chicken n-‐cam gene and a myosin heavy chain gene: Avian microchromosomes are not genetically inert reserves of DNA. J Exp Zool. 1993;265:295-‐300
29. Grupp IL, Subramaniam A, Hewett TE, Robbins J, Grupp G. Comparison of normal, hypodynamic, and hyperdynamic mouse hearts using isolated work-‐performing heart preparations. Am J Physiol. 1993;265:H1401-‐1410
30. Miller-‐Hance WC, LaCorbiere M, Fuller SJ, Evans SM, Lyons G, Schmidt C, Robbins J, Chien KR. In vitro chamber specification during embryonic stem cell cardiogenesis. Expression of the ventricular myosin light chain-‐2 gene is independent of heart tube formation. J Biol Chem. 1993;268:25244-‐25252
31. Moncman CL, Rindt H, Robbins J, Winkelmann DA. Segregated assembly of muscle myosin expressed in nonmuscle cells. Mol Biol Cell. 1993;4:1051-‐1067
32. Rindt H, Bauer BJ, Robbins J. In vitro production of enzymatically active myosin heavy chain. J Muscle Res Cell Motil. 1993;14:26-‐34
33. Rindt H, Gulick J, Knotts S, Neumann J, Robbins J. In vivo analysis of the murine beta-‐myosin heavy chain gene promoter. J Biol Chem. 1993;268:5332-‐5338
34. Robbins J. Gene targeting. The precise manipulation of the mammalian genome. Circ Res. 1993;73:3-‐9
35. Robbins J. Recombinant DNA and gene isolation. Trends Cardiovasc Med. 1993;3:39-‐43
36. Subramaniam A, Gulick J, Neumann J, Knotts S, Robbins J. Transgenic analysis of the thyroid-‐responsive elements in the alpha-‐cardiac myosin heavy chain gene promoter. J Biol Chem. 1993;268:4331-‐4336
37. Dorn GW, 2nd, Robbins J, Ball N, Walsh RA. Myosin heavy chain regulation and myocyte contractile depression after lv hypertrophy in aortic-‐banded mice. Am J Physiol. 1994;267:H400-‐405
38. Hewett TE, Grupp IL, Grupp G, Robbins J. Alpha-‐skeletal actin is associated with
20
increased contractility in the mouse heart. Circ Res. 1994;74:740-‐746 39. Jones WK, Sanchez A, Robbins J. Murine pulmonary myocardium: Developmental
analysis of cardiac gene expression. Dev Dyn. 1994;200:117-‐128 40. Knotts S, Rindt H, Neumann J, Robbins J. In vivo regulation of the mouse beta
myosin heavy chain gene. J Biol Chem. 1994;269:31275-‐31282 41. Sanchez A, Robbins J. Unprocessed myogenin transcripts accumulate during mouse
embryogenesis. J Biol Chem. 1994;269:1587-‐1590 42. Knotts S, Rindt H, Robbins J. Position independent expression and developmental
regulation is directed by the beta myosin heavy chain gene's 5' upstream region in transgenic mice. Nucleic Acids Res. 1995;23:3301-‐3309
43. Palermo J, Gulick J, Ng W, Grupp IL, Grupp G, Robbins J. Remodeling the mammalian heart using transgenesis. Cell Mol Biol Res. 1995;41:501-‐509
44. Rindt H, Knotts S, Robbins J. Segregation of cardiac and skeletal muscle-‐specific regulatory elements of the beta-‐myosin heavy chain gene. Proc Natl Acad Sci U S A. 1995;92:1540-‐1544
45. Rindt H, Subramaniam A, Robbins J. An in vivo analysis of transcriptional elements in the mouse alpha-‐myosin heavy chain gene promoter. Transgenic Res. 1995;4:397-‐405
46. Robbins J, Palermo J, Rindt H. In vivo definition of a cardiac specific promoter and its potential utility in remodeling the heart. Ann N Y Acad Sci. 1995;752:492-‐505
47. Colbert MC, Kirby ML, Robbins J. Endogenous retinoic acid signaling colocalizes with advanced expression of the adult smooth muscle myosin heavy chain isoform during development of the ductus arteriosus. Circ Res. 1996;78:790-‐798
48. Jones WK, Grupp IL, Doetschman T, Grupp G, Osinska H, Hewett TE, Boivin G, Gulick J, Ng WA, Robbins J. Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart. J Clin Invest. 1996;98:1906-‐1917
49. Knotts S, Sanchez A, Rindt H, Robbins J. Developmental modulation of a beta myosin heavy chain promoter-‐driven transgene. Dev Dyn. 1996;206:182-‐192
50. Palermo J, Gulick J, Colbert M, Fewell J, Robbins J. Transgenic remodeling of the contractile apparatus in the mammalian heart. Circ Res. 1996;78:504-‐509
51. Robbins J. Hypertrophic cardiomyopathy: A case study in converging pathways. J Clin Invest. 1996;98:2433-‐2434
52. Robbins J. Regulation of cardiac gene expression during development. Cardiovasc Res. 1996;31 Spec No:E2-‐16
53. Colbert MC, Hall DG, Kimball TR, Witt SA, Lorenz JN, Kirby ML, Hewett TE, Klevitsky R, Robbins J. Cardiac compartment-‐specific overexpression of a modified retinoic acid receptor produces dilated cardiomyopathy and congestive heart failure in transgenic mice. J Clin Invest. 1997;100:1958-‐1968
54. Fewell JG, Osinska H, Klevitsky R, Ng W, Sfyris G, Bahrehmand F, Robbins J. A treadmill exercise regimen for identifying cardiovascular phenotypes in transgenic mice. Am J Physiol. 1997;273:H1595-‐1605
55. Gulick J, Hewett TE, Klevitsky R, Buck SH, Moss RL, Robbins J. Transgenic remodeling of the regulatory myosin light chains in the mammalian heart. Circ Res. 1997;80:655-‐664
56. James J, Robbins J. Molecular remodeling of cardiac contractile function. Am J Physiol. 1997;273:H2105-‐2118
21
57. Kumar A, Crawford K, Close L, Madison M, Lorenz J, Doetschman T, Pawlowski S, Duffy J, Neumann J, Robbins J, Boivin GP, O'Toole BA, Lessard JL. Rescue of cardiac alpha-‐actin-‐deficient mice by enteric smooth muscle gamma-‐actin. Proc Natl Acad Sci U S A. 1997;94:4406-‐4411
58. Lorenz JN, Robbins J. Measurement of intraventricular pressure and cardiac performance in the intact closed-‐chest anesthetized mouse. Am J Physiol. 1997;272:H1137-‐1146
59. Ng WA, Doetschman T, Robbins J, Lessard JL. Muscle isoactin expression during in vitro differentiation of murine embryonic stem cells. Pediatr Res. 1997;41:285-‐292
60. Robbins J. Altering cardiac function via transgenesis a nuts and bolts approach. Trends Cardiovasc Med. 1997;7:185-‐191
61. Fewell JG, Hewett TE, Sanbe A, Klevitsky R, Hayes E, Warshaw D, Maughan D, Robbins J. Functional significance of cardiac myosin essential light chain isoform switching in transgenic mice. J Clin Invest. 1998;101:2630-‐2639
62. James JF, Hewett TE, Robbins J. Cardiac physiology in transgenic mice. Circ Res. 1998;82:407-‐415
63. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-‐dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-‐228
64. Pawloski-‐Dahm CM, Song G, Kirkpatrick DL, Palermo J, Gulick J, Dorn GW, 2nd, Robbins J, Walsh RA. Effects of total replacement of atrial myosin light chain-‐2 with the ventricular isoform in atrial myocytes of transgenic mice. Circulation. 1998;97:1508-‐1513
65. Robbins J. Alpha-‐tropomyosin knockouts: A blow against transcriptional chauvinism. Circ Res. 1998;82:134-‐136
66. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, Colbert MC, Gualberto A, Wieczorek DF, Molkentin JD. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 1998;281:1690-‐1693
67. Tardiff JC, Factor SM, Tompkins BD, Hewett TE, Palmer BM, Moore RL, Schwartz S, Robbins J, Leinwand LA. A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. J Clin Invest. 1998;101:2800-‐2811
68. Yang Q, Sanbe A, Osinska H, Hewett TE, Klevitsky R, Robbins J. A mouse model of myosin binding protein c human familial hypertrophic cardiomyopathy. J Clin Invest. 1998;102:1292-‐1300
69. Buck SH, Konyn PJ, Palermo J, Robbins J, Moss RL. Altered kinetics of contraction of mouse atrial myocytes expressing ventricular myosin regulatory light chain. Am J Physiol. 1999;276:H1167-‐1171
70. James J, Osinska H, Hewett TE, Kimball T, Klevitsky R, Witt S, Hall DG, Gulick J, Robbins J. Transgenic over-‐expression of a motor protein at high levels results in severe cardiac pathology. Transgenic Res. 1999;8:9-‐22
71. Sanbe A, Fewell JG, Gulick J, Osinska H, Lorenz J, Hall DG, Murray LA, Kimball TR, Witt SA, Robbins J. Abnormal cardiac structure and function in mice expressing nonphosphorylatable cardiac regulatory myosin light chain 2. J Biol Chem. 1999;274:21085-‐21094
72. Tardiff JC, Hewett TE, Palmer BM, Olsson C, Factor SM, Moore RL, Robbins J,
22
Leinwand LA. Cardiac troponin T mutations result in allele-‐specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest. 1999;104:469-‐481
73. Yang Q, Sanbe A, Osinska H, Hewett TE, Klevitsky R, Robbins J. In vivo modeling of myosin binding protein c familial hypertrophic cardiomyopathy. Circ Res. 1999;85:841-‐847
74. James J, Sanbe A, Yager K, Martin L, Klevitsky R, Robbins J. Genetic manipulation of the rabbit heart via transgenesis. Circulation. 2000;101:1715-‐1721
75. James J, Zhang Y, Osinska H, Sanbe A, Klevitsky R, Hewett TE, Robbins J. Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy. Circ Res. 2000;87:805-‐811
76. Mochly-‐Rosen D, Wu G, Hahn H, Osinska H, Liron T, Lorenz JN, Yatani A, Robbins J, Dorn GW, 2nd. Cardiotrophic effects of protein kinase c epsilon: Analysis by in vivo modulation of PKCε translocation. Circ Res. 2000;86:1173-‐1179
77. Nelson DP, Setser E, Hall DG, Schwartz SM, Hewitt T, Klevitsky R, Osinska H, Bellgrau D, Duke RC, Robbins J. Proinflammatory consequences of transgenic fas ligand expression in the heart. J Clin Invest. 2000;105:1199-‐1208
78. Robbins J. Toward the new millennium. Annu Rev Physiol. 2000;62:961-‐963 79. Robbins J. Remodeling the cardiac sarcomere using transgenesis. Annu Rev Physiol.
2000;62:261-‐287 80. Robbins J, Dorn GW, 2nd. Listening for hoof beats in heart beats. Nat Med.
2000;6:968-‐970 81. Sanbe A, Gulick J, Hayes E, Warshaw D, Osinska H, Chan CB, Klevitsky R, Robbins J.
Myosin light chain replacement in the heart. Am J Physiol Heart Circ Physiol. 2000;279:H1355-‐1364
82. Sanbe A, Nelson D, Gulick J, Setser E, Osinska H, Wang X, Hewett TE, Klevitsky R, Hayes E, Warshaw DM, Robbins J. In vivo analysis of an essential myosin light chain mutation linked to familial hypertrophic cardiomyopathy. Circ Res. 2000;87:296-‐302
83. Tardiff JC, Hewett TE, Factor SM, Vikstrom KL, Robbins J, Leinwand LA. Expression of the beta (slow)-‐isoform of myosin heavy chain in the adult mouse heart causes dominant-‐negative functional effects. Am J Physiol Heart Circ Physiol. 2000;278:H412-‐419
84. Dalloz F, Osinska H, Robbins J. Manipulating the contractile apparatus: Genetically defined animal models of cardiovascular disease. J Mol Cell Cardiol. 2001;33:9-‐25
85. Dalloz F, Osinska H, Robbins J. [genetically modified animal models in cardiovascular research]. Rev Esp Cardiol. 2001;54:764-‐789
86. Krenz M, Robbins J. Gates of fate. J Mol Cell Cardiol. 2001;33:2079-‐2082 87. Robbins J. Gene therapy and molecular toxicology: A commentary. Cardiovasc
Toxicol. 2001;1:3-‐5 88. Sanbe A, Gulick J, Fewell J, Robbins J. Examining the in vivo role of the amino
terminus of the essential myosin light chain. J Biol Chem. 2001;276:32682-‐32686 89. Schwartzbauer G, Robbins J. The tumor suppressor gene PTEN can regulate cardiac
hypertrophy and survival. J Biol Chem. 2001;276:35786-‐35793 90. Schwartzbauer G, Robbins J. Matters of sex: Sex matters. Circulation.
2001;104:1333-‐1335 91. Sze RW, Chan CB, Dardzinski BJ, Dunn S, Sanbe A, Schmithorst V, Robbins J, Holland
23
SK, Strife JL. Three-‐dimensional MR microscopy of a transgenic mouse model of dilated cardiomyopathy. Pediatr Radiol. 2001;31:55-‐61
92. Wang X, Osinska H, Dorn GW, 2nd, Nieman M, Lorenz JN, Gerdes AM, Witt S, Kimball T, Gulick J, Robbins J. Mouse model of desmin-‐related cardiomyopathy. Circulation. 2001;103:2402-‐2407
93. Wang X, Osinska H, Klevitsky R, Gerdes AM, Nieman M, Lorenz J, Hewett T, Robbins J. Expression of r120g-‐alphab-‐crystallin causes aberrant desmin and αB-‐crystallin aggregation and cardiomyopathy in mice. Circ Res. 2001;89:84-‐91
94. Wu G, Yussman MG, Barrett TJ, Hahn HS, Osinska H, Hilliard GM, Wang X, Toyokawa T, Yatani A, Lynch RA, Robbins J, Dorn GW, 2nd. Increased myocardial rab gtpase expression: A consequence and cause of cardiomyopathy. Circ Res. 2001;89:1130-‐1137
95. Yang Q, Hewett TE, Klevitsky R, Sanbe A, Wang X, Robbins J. PKA-‐dependent phosphorylation of cardiac myosin binding protein c in transgenic mice. Cardiovasc Res. 2001;51:80-‐88
96. Yang Q, Osinska H, Klevitsky R, Robbins J. Phenotypic deficits in mice expressing a myosin binding protein c lacking the titin and myosin binding domains. J Mol Cell Cardiol. 2001;33:1649-‐1658
97. Alpert NR, Brosseau C, Federico A, Krenz M, Robbins J, Warshaw DM. Molecular mechanics of mouse cardiac myosin isoforms. Am J Physiol Heart Circ Physiol. 2002;283:H1446-‐1454
98. Chu G, Carr AN, Young KB, Lester JW, Yatani A, Sanbe A, Colbert MC, Schwartz SM, Frank KF, Lampe PD, Robbins J, Molkentin JD, Kranias EG. Enhanced myocyte contractility and Ca2+ handling in a calcineurin transgenic model of heart failure. Cardiovasc Res. 2002;54:105-‐116
99. Hahn HS, Yussman MG, Toyokawa T, Marreez Y, Barrett TJ, Hilty KC, Osinska H, Robbins J, Dorn GW, 2nd. Ischemic protection and myofibrillar cardiomyopathy: Dose-‐dependent effects of in vivo δPKC inhibition. Circ Res. 2002;91:741-‐748
100. James J, Zhang Y, Wright K, Witt S, Glascock E, Osinska H, Klevitsky R, Martin L, Yager K, Sanbe A, Robbins J. Transgenic rabbits expressing mutant essential light chain do not develop hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2002;34:873-‐882
101. Lerman I, Harrison BC, Freeman K, Hewett TE, Allen DL, Robbins J, Leinwand LA. Genetic variability in forced and voluntary endurance exercise performance in seven inbred mouse strains. J Appl Physiol. 2002;92:2245-‐2255
102. Robbins J, Benson DW. Structure-‐function relationships in myosin binding protein-‐c: Taking off the blinders and collaring hypertrophic cardiomyopathy. Circ Res. 2002;91:656-‐658
103. Schwartzbauer G, Robbins J. The ADAMs: A new therapeutic avenue? Pharmacogenomics J. 2002;2:73-‐74
104. Wang X, Osinska H, Gerdes AM, Robbins J. Desmin filaments and cardiac disease: Establishing causality. J Card Fail. 2002;8:S287-‐292
105. Dorn GW, 2nd, Robbins J, Sugden PH. Phenotyping hypertrophy: Eschew obfuscation. Circ Res. 2003;92:1171-‐1175
106. Ishibashi Y, Takahashi M, Isomatsu Y, Qiao F, Iijima Y, Shiraishi H, Simsic JM, Baicu
24
CF, Robbins J, Zile MR, Cooper Gt. Role of microtubules versus myosin heavy chain isoforms in contractile dysfunction of hypertrophied murine cardiocytes. Am J Physiol Heart Circ Physiol. 2003;285:H1270-‐1285
107. Krenz M, Sanbe A, Bouyer-‐Dalloz F, Gulick J, Klevitsky R, Hewett TE, Osinska HE, Lorenz JN, Brosseau C, Federico A, Alpert NR, Warshaw DM, Perryman MB, Helmke SM, Robbins J. Analysis of myosin heavy chain functionality in the heart. J Biol Chem. 2003;278:17466-‐17474
108. Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska H, Robbins J. Reengineering inducible cardiac-‐specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res. 2003;92:609-‐616
109. Vernachio J, Bayer AS, Le T, Chai YL, Prater B, Schneider A, Ames B, Syribeys P, Robbins J, Patti JM. Anti-‐clumping factor A immunoglobulin reduces the duration of methicillin-‐resistant staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob Agents Chemother. 2003;47:3400-‐3406
110. Wang X, Klevitsky R, Huang W, Glasford J, Li F, Robbins J. Alphab-‐crystallin modulates protein aggregation of abnormal desmin. Circ Res. 2003;93:998-‐1005
111. Yan X, Price RL, Nakayama M, Ito K, Schuldt AJ, Manning WJ, Sanbe A, Borg TK, Robbins J, Lorell BH. Ventricular-‐specific expression of angiotensin ii type 2 receptors causes dilated cardiomyopathy and heart failure in transgenic mice. Am J Physiol Heart Circ Physiol. 2003;285:H2179-‐2187
112. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R, Kimball TF, Lorenz JN, Nairn AC, Liggett SB, Bodi I, Wang S, Schwartz A, Lakatta EG, DePaoli-‐Roach AA, Robbins J, Hewett TE, Bibb JA, Westfall MV, Kranias EG, Molkentin JD. PKCα regulates cardiac contractility and propensity toward heart failure. Nat Med. 2004;10:248-‐254
113. Gaffin RD, Gokulan K, Sacchettini JC, Hewett T, Klevitsky R, Robbins J, Muthuchamy M. Charged residue changes in the carboxy-‐terminus of alpha-‐tropomyosin alter mouse cardiac muscle contractility. J Physiol. 2004;556:531-‐543
114. Gaffin RD, Tong CW, Zawieja DC, Hewett TE, Klevitsky R, Robbins J, Muthuchamy M. Charged residue alterations in the inner-‐core domain and carboxy-‐terminus of alpha-‐tropomyosin differentially affect mouse cardiac muscle contractility. J Physiol. 2004;561:777-‐791
115. Krenz M, Robbins J. Impact of beta-‐myosin heavy chain expression on cardiac function during stress. J Am Coll Cardiol. 2004;44:2390-‐2397
116. Kumar A, Crawford K, Flick R, Klevitsky R, Lorenz JN, Bove KE, Robbins J, Lessard JL. Transgenic overexpression of cardiac actin in the mouse heart suggests coregulation of cardiac, skeletal and vascular actin expression. Transgenic Res. 2004;13:531-‐540
117. Odley A, Hahn HS, Lynch RA, Marreez Y, Osinska H, Robbins J, Dorn GW, 2nd. Regulation of cardiac contractility by rab4-‐modulated beta2-‐adrenergic receptor recycling. Proc Natl Acad Sci U S A. 2004;101:7082-‐7087
118. Robbins J. Genetic modification of the heart: Exploring necessity and sufficiency in the past 10 years. J Mol Cell Cardiol. 2004;36:643-‐652
119. Sanbe A, Osinska H, Saffitz JE, Glabe CG, Kayed R, Maloyan A, Robbins J. Desmin-‐related cardiomyopathy in transgenic mice: A cardiac amyloidosis. Proc Natl Acad Sci U S A. 2004;101:10132-‐10136
25
120. Song Q, Young KB, Chu G, Gulick J, Gerst M, Grupp IL, Robbins J, Kranias EG. Overexpression of phospholamban in slow-‐twitch skeletal muscle is associated with depressed contractile function and muscle remodeling. FASEB J. 2004;18:974-‐976
121. Syed F, Odley A, Hahn HS, Brunskill EW, Lynch RA, Marreez Y, Sanbe A, Robbins J, Dorn GW, 2nd. Physiological growth synergizes with pathological genes in experimental cardiomyopathy. Circ Res. 2004;95:1200-‐1206
122. Wei L, Taffet GE, Khoury DS, Bo J, Li Y, Yatani A, Delaughter MC, Klevitsky R, Hewett TE, Robbins J, Michael LH, Schneider MD, Entman ML, Schwartz RJ. Disruption of rho signaling results in progressive atrioventricular conduction defects while ventricular function remains preserved. Faseb J. 2004;18:857-‐859
123. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J, Molkentin JD. Loss of cyclophilin d reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434:658-‐662
124. den Engelsman J, Gerrits D, de Jong WW, Robbins J, Kato K, Boelens WC. Nuclear import of {alpha}b-‐crystallin is phosphorylation-‐dependent and hampered by hyperphosphorylation of the myopathy-‐related mutant R120G. J Biol Chem. 2005;280:37139-‐37148
125. Gard JJ, Yamada K, Green KG, Eloff BC, Rosenbaum DS, Wang X, Robbins J, Schuessler RB, Yamada KA, Saffitz JE. Remodeling of gap junctions and slow conduction in a mouse model of desmin-‐related cardiomyopathy. Cardiovasc Res. 2005;67:539-‐547
126. Graham DR, Garnham CP, Fu Q, Robbins J, Van Eyk JE. Improvements in two-‐dimensional gel electrophoresis by utilizing a low cost "in-‐house" neutral ph sodium dodecyl sulfate-‐polyacrylamide gel electrophoresis system. Proteomics. 2005;5:2309-‐2314
127. Gulick J, Robbins J. Regulation of transgene expression using tetracycline. Current protocols in molecular biology. John Wiley & Sons, Inc.; 2005:23.12.21-‐23.12.28.
128. James J, Martin L, Krenz M, Quatman C, Jones F, Klevitsky R, Gulick J, Robbins J. Forced expression of alpha-‐myosin heavy chain in the rabbit ventricle results in cardioprotection under cardiomyopathic conditions. Circulation. 2005;111:2339-‐2346
129. Krenz M, Yutzey KE, Robbins J. Noonan syndrome mutation q79r in shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-‐regulated kinase 1/2 signaling. Circ Res. 2005;97:813-‐820
130. Kruger M, Zittrich S, Redwood C, Blaudeck N, James J, Robbins J, Pfitzer G, Stehle R. Effects of the mutation R145G in human cardiac troponin I on the kinetics of the contraction-‐relaxation cycle in isolated cardiac myofibrils. J Physiol. 2005;564:347-‐357
131. Maloyan A, Sanbe A, Osinska H, Westfall M, Robinson D, Imahashi K, Murphy E, Robbins J. Mitochondrial dysfunction and apoptosis underlie the pathogenic process in αB-‐crystallin desmin-‐related cardiomyopathy. Circulation. 2005;112:3451-‐3461
132. Miller MS, Palmer BM, Ruch S, Martin LA, Farman GP, Wang Y, Robbins J, Irving TC, Maughan DW. The essential light chain N-‐terminal extension alters force and fiber kinetics in mouse cardiac muscle. J Biol Chem. 2005;280:34427-‐34434
26
133. Nakayama M, Yan X, Price RL, Borg TK, Ito K, Sanbe A, Robbins J, Lorell BH. Chronic ventricular myocyte-‐specific overexpression of angiotensin II type 2 receptor results in intrinsic myocyte contractile dysfunction. Am J Physiol Heart Circ Physiol. 2005;288:H317-‐327
134. Sadayappan S, Gulick J, Osinska H, Martin LA, Hahn HS, Dorn GW, 2nd, Klevitsky R, Seidman CE, Seidman JG, Robbins J. Cardiac myosin-‐binding protein-‐C phosphorylation and cardiac function. Circ Res. 2005;97:1156-‐1163
135. Sakthivel S, Finley NL, Rosevear PR, Lorenz JN, Gulick J, Kim S, VanBuren P, Martin LA, Robbins J. In vivo and in vitro analysis of cardiac troponin I phosphorylation. J Biol Chem. 2005;280:703-‐714
136. Sanbe A, James J, Tuzcu V, Nas S, Martin L, Gulick J, Osinska H, Sakthivel S, Klevitsky R, Ginsburg KS, Bers DM, Zinman B, Lakatta EG, Robbins J. Transgenic rabbit model for human troponin I-‐based hypertrophic cardiomyopathy. Circulation. 2005;111:2330-‐2338
137. Sanbe A, Osinska H, Villa C, Gulick J, Klevitsky R, Glabe CG, Kayed R, Robbins J. Reversal of amyloid-‐induced heart disease in desmin-‐related cardiomyopathy. Proc Natl Acad Sci U S A. 2005;102:13592-‐13597
138. Yutzey KE, Colbert M, Robbins J. Ras-‐related signaling pathways in valve development: Ebb and flow. Physiology (Bethesda). 2005;20:390-‐397
139. Dias FA, Walker LA, Arteaga GM, Walker JS, Vijayan K, Pena JR, Ke Y, Fogaca RT, Sanbe A, Robbins J, Wolska BM. The effect of myosin regulatory light chain phosphorylation on the frequency-‐dependent regulation of cardiac function. J Mol Cell Cardiol. 2006;41:330-‐339
140. Funakoshi H, Chan TO, Good JC, Libonati JR, Piuhola J, Chen X, MacDonnell SM, Lee LL, Herrmann DE, Zhang J, Martini J, Palmer TM, Sanbe A, Robbins J, Houser SR, Koch WJ, Feldman AM. Regulated overexpression of the a1-‐adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function. Circulation. 2006;114:2240-‐2250
141. Gaffin RD, Gokulan K, Sacchettini JC, Hewett TE, Klevitsky R, Robbins J, Sarin V, Zawieja DC, Meininger GA, Muthuchamy M. Changes in end-‐to-‐end interactions of tropomyosin affect mouse cardiac muscle dynamics. Am J Physiol Heart Circ Physiol. 2006;291:H552-‐563
142. Nakamura T, Colbert MC, Robbins J. Neural crest cells retain multipotential characteristics in the developing valves and label the cardiac conduction system. Circ Res. 2006;98:1547-‐1554
143. Nishizawa T, Vatner SF, Hong C, Shen YT, Hardt SE, Robbins J, Ishikawa Y, Sadoshima J, Vatner DE. Overexpressed cardiac GSα in rabbits. J Mol Cell Cardiol. 2006;41:44-‐50
144. Sadayappan S, Osinska H, Klevitsky R, Lorenz JN, Sargent M, Molkentin JD, Seidman CE, Seidman JG, Robbins J. Cardiac myosin binding protein C phosphorylation is cardioprotective. Proc Natl Acad Sci U S A. 2006;103:16918-‐16923
145. Tallini YN, Ohkura M, Choi BR, Ji G, Imoto K, Doran R, Lee J, Plan P, Wilson J, Xin HB, Sanbe A, Gulick J, Mathai J, Robbins J, Salama G, Nakai J, Kotlikoff MI. Imaging cellular signals in the heart in vivo: Cardiac expression of the high-‐signal Ca2+ indicator gcAMP2. Proc Natl Acad Sci U S A. 2006;103:4753-‐4758
27
146. Wang H, Grant JE, Doede CM, Sadayappan S, Robbins J, Walker JW. PKC-‐βII sensitizes cardiac myofilaments to Ca2+ by phosphorylating troponin I on threonine-‐144. J Mol Cell Cardiol. 2006;41:823-‐833
147. Wang X, Robbins J. Heart failure and protein quality control. Circ Res. 2006;99:1315-‐1328
148. Diwan A, Krenz M, Syed FM, Wansapura J, Ren X, Koesters AG, Li H, Kirshenbaum LA, Hahn HS, Robbins J, Jones WK, Dorn GW. Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of bnip3 restrains postinfarction remodeling in mice. J Clin Invest. 2007;117:2825-‐2833
149. Galvez AS, Diwan A, Odley AM, Hahn HS, Osinska H, Melendez JG, Robbins J, Lynch RA, Marreez Y, Dorn GW, 2nd. Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. Circ Res. 2007;100:1071-‐1078
150. Hambleton M, York A, Sargent MA, Kaiser RA, Lorenz JN, Robbins J, Molkentin JD. Inducible and myocyte-‐specific inhibition of PKCα enhances cardiac contractility and protects against infarction-‐induced heart failure. Am J Physiol Heart Circ Physiol. 2007;293:H3768-‐3771
151. Heineke J, Auger-‐Messier M, Xu J, Oka T, Sargent MA, York A, Klevitsky R, Vaikunth S, Duncan SA, Aronow BJ, Robbins J, Crombleholme TM, Molkentin JD. Cardiomyocyte GATA4 functions as a stress-‐responsive regulator of angiogenesis in the murine heart. J Clin Invest. 2007;117:3198-‐3210
152. Hoyer K, Krenz M, Robbins J, Ingwall JS. Shifts in the myosin heavy chain isozymes in the mouse heart result in increased energy efficiency. J Mol Cell Cardiol. 2007;42:214-‐221
153. Hsieh PC, Segers VF, Davis ME, MacGillivray C, Gannon J, Molkentin JD, Robbins J, Lee RT. Evidence from a genetic fate-‐mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med. 2007;13:970-‐974
154. Krenz M, Sadayappan S, Osinska HE, Henry JA, Beck S, Warshaw DM, Robbins J. Distribution and structure-‐function relationship of myosin heavy chain isoforms in the adult mouse heart. J Biol Chem. 2007;282:24057-‐24064
155. Maloyan A, Gulick J, Glabe CG, Kayed R, Robbins J. Exercise reverses preamyloid oligomer and prolongs survival in αB-‐crystallin-‐based desmin-‐related cardiomyopathy. Proc Natl Acad Sci U S A. 2007;104:5995-‐6000
156. Nagayama T, Takimoto E, Sadayappan S, Mudd JO, Seidman JG, Robbins J, Kass DA. Control of in vivo left ventricular [correction] contraction/relaxation kinetics by myosin binding protein c: Protein kinase a phosphorylation dependent and independent regulation. Circulation. 2007;116:2399-‐2408
157. Nakamura T, Colbert M, Krenz M, Molkentin JD, Hahn HS, Dorn GW, 2nd, Robbins J. Mediating erk 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J Clin Invest. 2007;117:2123-‐2132
158. Nakayama H, Chen X, Baines CP, Klevitsky R, Zhang X, Zhang H, Jaleel N, Chua BH, Hewett TE, Robbins J, Houser SR, Molkentin JD. Ca2+-‐ and mitochondrial-‐dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest. 2007;117:2431-‐2444
159. Nishizawa T, Shen YT, Rossi F, Hong C, Robbins J, Ishikawa Y, Sadoshima J, Vatner DE, Vatner SF. Altered autonomic control in conscious transgenic rabbits with
28
overexpressed cardiac GSα Am J Physiol Heart Circ Physiol. 2007;292:H971-‐975 160. Oka T, Xu J, Kaiser RA, Melendez J, Hambleton M, Sargent MA, Lorts A, Brunskill EW,
Dorn GW, 2nd, Conway SJ, Aronow BJ, Robbins J, Molkentin JD. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res. 2007;101:313-‐321
161. Purcell NH, Wilkins BJ, York A, Saba-‐El-‐Leil MK, Meloche S, Robbins J, Molkentin JD. Genetic inhibition of cardiac ERK1/2 promotes stress-‐induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci U S A. 2007;104:14074-‐14079
162. Yasuda S, Coutu P, Sadayappan S, Robbins J, Metzger JM. Cardiac transgenic and gene transfer strategies converge to support an important role for troponin I in regulating relaxation in cardiac myocytes. Circ Res. 2007;101:377-‐386
163. Yutzey KE, Robbins J. Principles of genetic murine models for cardiac disease. Circulation. 2007;115:792-‐799
164. Jaleel N, Nakayama H, Chen X, Kubo H, MacDonnell S, Zhang H, Berretta R, Robbins J, Cribbs L, Molkentin JD, Houser SR. Ca2+ influx through t-‐ and l-‐type Ca2+ channels have different effects on myocyte contractility and induce unique cardiac phenotypes. Circ Res. 2008;103:1109-‐1119
165. Krenz M, Gulick J, Osinska HE, Colbert MC, Molkentin JD, Robbins J. Role of ERK1/2 signaling in congenital valve malformations in noonan syndrome. Proc Natl Acad Sci U S A. 2008;105:18930-‐18935
166. Lowey S, Lesko LM, Rovner AS, Hodges AR, White SL, Low RB, Rincon M, Gulick J, Robbins J. Functional effects of the hypertrophic cardiomyopathy R403Q mutation are different in an alpha-‐ or beta-‐myosin heavy chain backbone. J Biol Chem. 2008;283:20579-‐20589
167. Millay DP, Sargent MA, Osinska H, Baines CP, Barton ER, Vuagniaux G, Sweeney HL, Robbins J, Molkentin JD. Genetic and pharmacologic inhibition of mitochondrial-‐dependent necrosis attenuates muscular dystrophy. Nat Med. 2008;14:442-‐447
168. Moga MA, Nakamura T, Robbins J. Genetic approaches for changing the heart and dissecting complex syndromes. J Mol Cell Cardiol. 2008;45:148-‐155
169. Pattison JS, Robbins J. Protein misfolding and cardiac disease: Establishing cause and effect. Autophagy. 2008;4:821-‐823
170. Pattison JS, Sanbe A, Maloyan A, Osinska H, Klevitsky R, Robbins J. Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure. Circulation. 2008;117:2743-‐2751
171. Pattison JS, Waggoner JR, James J, Martin L, Gulick J, Osinska H, Klevitsky R, Kranias EG, Robbins J. Phospholamban overexpression in transgenic rabbits. Transgenic Res. 2008;17:157-‐170
172. Pinz I, Ostroy SE, Hoyer K, Osinska H, Robbins J, Molkentin JD, Ingwall JS. Calcineurin-‐induced energy wasting in a transgenic mouse model of heart failure. Am J Physiol Heart Circ Physiol. 2008;294:H1459-‐1466
173. Pinz I, Robbins J, Rajasekaran NS, Benjamin IJ, Ingwall JS. Unmasking different mechanical and energetic roles for the small heat shock proteins CryAB and HSPB2 using genetically modified mouse hearts. Faseb J. 2008;22:84-‐92
174. Sadayappan S, Finley N, Howarth JW, Osinska H, Klevitsky R, Lorenz JN, Rosevear PR, Robbins J. Role of the acidic N' region of cardiac troponin I in regulating
29
myocardial function. FASEB J. 2008;22:1246-‐1257 175. Sadayappan S, Robbins J. The death of transcriptional chauvinism in the control and
regulation of cardiac contractility. Ann N Y Acad Sci. 2008;1123:1-‐9 176. Wolf CM, Arad M, Ahmad F, Sanbe A, Bernstein SA, Toka O, Konno T, Morley G,
Robbins J, Seidman JG, Seidman CE, Berul CI. Reversibility of prkag2 glycogen-‐storage cardiomyopathy and electrophysiological manifestations. Circulation. 2008;117:144-‐154
177. Yano N, Tseng A, Zhao TC, Robbins J, Padbury JF, Tseng YT. Temporally controlled overexpression of cardiac-‐specific pi3Kα induces enhanced myocardial contractility-‐-‐a new transgenic model. Am J Physiol Heart Circ Physiol. 2008;295:H1690-‐1694
178. Gulick J, Robbins J. Cell-‐type-‐specific transgenesis in the mouse. Methods Mol Biol. 2009;561:91-‐104
179. Huang H, Macgillivray C, Kwon HS, Lammerding J, Robbins J, Lee RT, So P. Three-‐dimensional cardiac architecture determined by two-‐photon microtomy. J Biomed Opt. 2009;14:044029
180. Maloyan A, Osinska H, Lammerding J, Lee RT, Cingolani OH, Kass DA, Lorenz JN, Robbins J. Biochemical and mechanical dysfunction in a mouse model of desmin-‐related myopathy. Circ Res. 2009;104:1021-‐1028
181. Molkentin JD, Robbins J. With great power comes great responsibility: Using mouse genetics to study cardiac hypertrophy and failure. J Mol Cell Cardiol. 2009;46:130-‐136
182. Nakamura T, Gulick J, Colbert MC, Robbins J. Protein tyrosine phosphatase activity in the neural crest is essential for normal heart and skull development. Proc Natl Acad Sci U S A. 2009;106:11270-‐11275
183. Nakamura T, Gulick J, Pratt R, Robbins J. Noonan syndrome is associated with enhanced perk activity, the repression of which can prevent craniofacial malformations. Proc Natl Acad Sci U S A. 2009;106:15436-‐15441
184. Nakayama H, Bodi I, Correll RN, Chen X, Lorenz J, Houser SR, Robbins J, Schwartz A, Molkentin JD. Alpha1g-‐dependent t-‐type Ca2+ current antagonizes cardiac hypertrophy through a nos3-‐dependent mechanism in mice. J Clin Invest. 2009;119:3787-‐3796
185. Nicolaou P, Rodriguez P, Ren X, Zhou X, Qian J, Sadayappan S, Mitton B, Pathak A, Robbins J, Hajjar RJ, Jones K, Kranias EG. Inducible expression of active protein phosphatase-‐1 inhibitor-‐1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ Res. 2009;104:1012-‐1020
186. Sadayappan S, Gulick J, Klevitsky R, Lorenz JN, Sargent M, Molkentin JD, Robbins J. Cardiac myosin binding protein-‐c phosphorylation in a {beta}-‐myosin heavy chain background. Circulation. 2009;119:1253-‐1262
187. Scruggs SB, Hinken AC, Thawornkaiwong A, Robbins J, Walker LA, de Tombe PP, Geenen DL, Buttrick PM, Solaro RJ. Ablation of ventricular myosin regulatory light chain phosphorylation in mice causes cardiac dysfunction in situ and affects neighboring myofilament protein phosphorylation. J Biol Chem. 2009;284:5097-‐5106
188. Suzuki T, Palmer BM, James J, Wang Y, Chen Z, VanBuren P, Maughan DW, Robbins J, LeWinter MM. Effects of cardiac myosin isoform variation on myofilament function
30
and crossbridge kinetics in transgenic rabbits. Circ Heart Fail. 2009;2:334-‐341 189. Waggoner JR, Ginsburg KS, Mitton B, Haghighi K, Robbins J, Bers DM, Kranias EG.
Phospholamban overexpression in rabbit ventricular myocytes does not alter sarcoplasmic reticulum Ca2+ transport. Am J Physiol Heart Circ Physiol. 2009;296:H698-‐703
190. Wu X, Chang B, Blair NS, Sargent M, York AJ, Robbins J, Shull GE, Molkentin JD. Plasma membrane ca2+-‐ATPase isoform 4 antagonizes cardiac hypertrophy in association with calcineurin inhibition in rodents. J Clin Invest. 2009;119:976-‐985
191. Xiang FL, Lu X, Hammoud L, Zhu P, Chidiac P, Robbins J, Feng Q. Cardiomyocyte-‐specific overexpression of human stem cell factor improves cardiac function and survival after myocardial infarction in mice. Circulation. 2009;120:1065-‐1074, 1069 p following 1074
192. Bardswell SC, Cuello F, Rowland AJ, Sadayappan S, Robbins J, Gautel M, Walker JW, Kentish JC, Avkiran M. Distinct sarcomeric substrates are responsible for protein kinase D-‐mediated regulation of cardiac myofilament Ca2+ sensitivity and cross-‐bridge cycling. J Biol Chem. 2010;285:5674-‐5682
193. Heineke J, Wollert KC, Osinska H, Sargent MA, York AJ, Robbins J, Molkentin JD. Calcineurin protects the heart in a murine model of dilated cardiomyopathy. J Mol Cell Cardiol. 2010;48:1080-‐1087
194. James J, Hor K, Moga MA, Martin LA, Robbins J. Effects of myosin heavy chain manipulation in experimental heart failure. J Mol Cell Cardiol. 2010;48:999-‐1006
195. Maillet M, Davis J, Auger-‐Messier M, York A, Osinska H, Piquereau J, Lorenz JN, Robbins J, Ventura-‐Clapier R, Molkentin JD. Heart-‐specific deletion of cnb1 reveals multiple mechanisms whereby calcineurin regulates cardiac growth and function. J Biol Chem. 2010;285:6716-‐6724
196. Maloyan A, Robbins J. Autophagy in desmin-‐related cardiomyopathy: Thoughts at the halfway point. Autophagy. 2010;6
197. Maloyan A, Sayegh J, Osinska H, Chua BH, Robbins J. Manipulation of death pathways in desmin-‐related cardiomyopathy. Circ Res. 2010;106:1524-‐1532
198. Rice R, Guinto P, Dowell-‐Martino C, He H, Hoyer K, Krenz M, Robbins J, Ingwall JS, Tardiff JC. Cardiac myosin heavy chain isoform exchange alters the phenotype of cTNT-‐related cardiomyopathies in mouse hearts. J Mol Cell Cardiol. 2010;48:979-‐988
199. Terrell D, Robbins J. Protein conformation-‐based disease: Getting to the heart of the matter. Annu Rev Physiol. 2010;72:15-‐17
200. James J, Robbins J. Signaling and myosin-‐binding protein C. J Biol Chem. 2011;286:9913-‐9919
201. James J, Robbins J. At the source: Treating heart failure by altering muscle motor function. Circ Res. 2011;109:5-‐7
202. Li J, Horak KM, Su H, Sanbe A, Robbins J, Wang X. Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice. J Clin Invest. 2011;121:3689-‐3700
203. Li X, Chan TO, Myers V, Chowdhury I, Zhang XQ, Song J, Zhang J, Andrel J, Funakoshi H, Robbins J, Koch WJ, Hyslop T, Cheung JY, Feldman AM. Controlled and cardiac-‐restricted overexpression of the arginine vasopressin v1a receptor causes reversible left ventricular dysfunction through Gαq-‐mediated cell signaling. Circulation.
31
2011;124:572-‐581 204. McLendon PM, Robbins J. Desmin-‐related cardiomyopathy: An unfolding story. Am J
Physiol Heart Circ Physiol. 2011;301:H1220-‐1228 205. Mun JY, Gulick J, Robbins J, Woodhead J, Lehman W, Craig R. Electron microscopy
and 3D reconstruction of f-‐actin decorated with cardiac myosin-‐binding protein C. J Mol Biol. 2011;410:214-‐225
206. Palmer BM, Sadayappan S, Wang Y, Weith AE, Previs MJ, Bekyarova T, Irving TC, Robbins J, Maughan DW. Roles for cardiac MyBP-‐C in maintaining myofilament lattice rigidity and prolonging myosin cross-‐bridge lifetime. Biophys J. 2011;101:1661-‐1669
207. Pattison JS, Osinska H, Robbins J. Atg7 induces basal autophagy and rescues autophagic deficiency in CryABR120G cardiomyocytes. Circ Res. 2011;109:151-‐160
208. Pattison JS, Robbins J. Autophagy and proteotoxicity in cardiomyocytes. Autophagy. 2011;7:1259-‐1260
209. Robbins J. Twenty years of gene targeting: What we don't know. Circ Res. 2011;109:722-‐723
210. Sadayappan S, Gulick J, Osinska H, Barefield D, Cuello F, Avkiran M, Lasko VM, Lorenz JN, Maillet M, Martin JL, Brown JH, Bers DM, Molkentin JD, James J, Robbins J. A critical function for ser-‐282 in cardiac myosin binding protein-‐C phosphorylation and cardiac function. Circ Res. 2011;109:141-‐150
211. Stanley BA, Graham DR, James J, Mitsak M, Tarwater PM, Robbins J, Van Eyk JE. Altered myofilament stoichiometry in response to heart failure in a cardioprotective alpha-‐myosin heavy chain transgenic rabbit model. Proteomics Clin Appl. 2011;5:147-‐158
212. Weith A, Sadayappan S, Gulick J, Previs MJ, Vanburen P, Robbins J, Warshaw DM. Unique single molecule binding of cardiac myosin binding protein-‐C to actin and phosphorylation-‐dependent inhibition of actomyosin motility requires 17 amino acids of the motif domain. J Mol Cell Cardiol. 2011 52: 219-‐227
213. Bhuiyan MS, Gulick J, Osinska H, Gupta M, Robbins J. Determination of the critical residues responsible for cardiac myosin binding protein C's interactions. J Mol Cell Cardiol. 2012;53:838-‐847
214. Haghighi K, Pritchard T, Bossuyt J, Waggoner JR, Yuan Q, Fan GC, Osinska H, Anjak A, Rubinstein J, Robbins J, Bers DM, Kranias EG. The human phospholamban arg14-‐deletion mutant localizes to plasma membrane and interacts with the Na/K-‐ATPase. J Mol Cell Cardiol. 2012;52:773-‐782
215. Jeyaraj D, Haldar SM, Wan X, McCauley MD, Ripperger JA, Hu K, Lu Y, Eapen BL, Sharma N, Ficker E, Cutler MJ, Gulick J, Sanbe A, Robbins J, Demolombe S, Kondratov RV, Shea SA, Albrecht U, Wehrens XH, Rosenbaum DS, Jain MK. Circadian rhythms govern cardiac repolarization and arrhythmogenesis. Nature. 2012;483:96-‐99
216. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, …Robbins J,et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012;8:445-‐544
217. Liao X, Sluimer JC, Wang Y, Subramanian M, Brown K, Pattison JS, Robbins J, Martinez J, Tabas I. Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab. 2012;15:545-‐553
32
218. Lynch JM, Maillet M, Vanhoutte D, Schloemer A, Sargent MA, Blair NS, Lynch KA, Okada T, Aronow BJ, Osinska H, Prywes R, Lorenz JN, Mori K, Lawler J, Robbins J, Molkentin JD. A thrombospondin-‐dependent pathway for a protective ER stress response. Cell. 2012;149:1257-‐1268
219. Pattison JS, Robbins J. Desmin and heart disease. In: Kavallaris M, ed. Cytoskeleton and human disease. New York, NY: Humana Press; 2012:411-‐424.
220. Previs MJ, Beck Previs S, Gulick J, Robbins J, Warshaw DM. Molecular mechanics of cardiac myosin-‐binding protein C in native thick filaments. Science. 2012;337:1215-‐1218
221. Sciarretta S, Zhai P, Shao D, Maejima Y, Robbins J, Volpe M, Condorelli G, Sadoshima J. Rheb is a critical regulator of autophagy during myocardial ischemia: Pathophysiological implications in obesity and metabolic syndrome. Circulation. 2012;125:1134-‐1146
222. Tranter M, Liu Y, He S, Gulick J, Ren X, Robbins J, Jones WK, Reineke TM. In vivo delivery of nucleic acids via glycopolymer vehicles affords therapeutic infarct size reduction in vivo. Mol Ther. 2012;20:601-‐608
223. Weith A, Sadayappan S, Gulick J, Previs MJ, Vanburen P, Robbins J, Warshaw DM. Unique single molecule binding of cardiac myosin binding protein-‐C to actin and phosphorylation-‐dependent inhibition of actomyosin motility requires 17 amino acids of the motif domain. J Mol Cell Cardiol. 2012;52:219-‐227
224. Weith AE, Previs MJ, Hoeprich GJ, Previs SB, Gulick J, Robbins J, Warshaw DM. The extent of cardiac myosin binding protein-‐c phosphorylation modulates actomyosin function in a graded manner. J Muscle Res Cell Motil. 2012;33:449-‐459
225. Hinken AC, Hanft LM, Scruggs SB, Sadayappan S, Robbins J, Solaro RJ, McDonald KS. Protein kinase C depresses cardiac myocyte power output and attenuates myofilament responses induced by protein kinase A. J Muscle Res Cell Motil. 2012 Dec;33(6):439-‐48
226. James J, Robbins J. Ablating a cardiac protein: Causality at last. Circ Res. 2013;112:1415-‐1419
227. Lowey S, Bretton V, Gulick J, Robbins J, Trybus KM. Transgenic mouse alpha-‐ and beta-‐cardiac myosins containing the r403q mutation show isoform-‐dependent transient kinetic differences. J Biol Chem. 2013;288:14780-‐14787
228. Michalek AJ, Howarth JW, Gulick J, Previs MJ, Robbins J, Rosevear PR, Warshaw DM. Phosphorylation modulates the mechanical stability of the cardiac myosin-‐binding protein C motif. Biophys J. 2013;104:442-‐452
229. Wang Y, Tanner BC, Lombardo AT, Tremble SM, Maughan DW, Vanburen P, Lewinter MM, Robbins J, Palmer BM. Cardiac myosin isoforms exhibit differential rates of MgADP release and MgATP binding detected by myocardial viscoelasticity. J Mol Cell Cardiol. 2013;54:1-‐8
230. Xu X, Kobayashi S, Chen K, Timm D, Volden P, Huang Y, Gulick J, Yue Z, Robbins J, Epstein PN, Liang Q. Diminished autophagy limits cardiac injury in mouse models of type 1 diabetes. J Biol Chem. 2013;288:18077-‐18092
231. Karch J, Kwong JQ, Burr AR, Sargent MA, Elrod JW, Peixoto PM, Martinez-‐Caballero S, Osinska H, Cheng EH, Robbins J, Kinnally KW, Molkentin JD. Bax and Bak function as the outer membrane component of the mitochondrial permeability pore in regulating necrotic cell death in mice. eLife. 2013;2:e00772
33
232. Razzaque MA, Gupta M, Osinska H, Gulick J, Blaxall BC, Robbins J. An endogenously produced fragment of cardiac myosin-‐binding protein C is pathogenic and can lead to heart failure. Circ Res. 2013 Aug 16;113(5):553-‐61
233. Gupta MK, Gulick J, James J, Osinska H, Lorenz JN, Robbins J. Functional dissection of myosin binding protein C phosphorylation. J Mol Cell Cardiol. 2013;64C:39-‐50
234. Su H, Li J, Osinska H, Li F, Robbins J, Liu J, Wei N, Wang X. The cop9 signalosome is required for autophagy, proteasome-‐mediated proteolysis, and cardiomyocyte survival in adult mice. Circ Heart Fail. 2013;6:1049-‐1057
235. Bhuiyan MS, Pattison JS, Osinska H, James J, Gulick J, McLendon PM, Hill JA, Sadoshima J, Robbins J. Enhanced autophagy ameliorates cardiac proteinopathy. J Clin Invest. 2013;123(12):5284-‐97
236. Gupta MK, Robbins J. Post-‐translational control of cardiac hemodynamics through myosin binding protein C. Pflugers Archiv : European journal of physiology. 2014 Feb;466(2):231-‐6.
237. Mun JY, Previs MJ, Yu HY, Gulick J, Tobacman LS, Beck Previs S, Robbins J, Warshaw DM, Craig R. Myosin-‐binding protein C displaces tropomyosin to activate cardiac thin filaments and governs their speed by an independent mechanism. Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2170-‐5
238. Ehrman LA, Nardini D, Ehrman S, Rizvi TA, Gulick J, Krenz M, Dasgupta B, Robbins J, Ratner N, Nakafuku M, Waclaw RR. The protein tyrosine phosphatase shp2 is required for the generation of oligodendrocyte progenitor cells and myelination in the mouse telencephalon. J Neurosci. 2014 Mar 5;34(10):3767-‐78
239. Alves ML, Dias FA, Gaffin RD, Simon JN, Montminy EM, Biesiadecki BJ, Hinken AC, Warren CM, Utter MS, Davis RT, 3rd, Sadayappan S, Robbins J, Wieczorek DF, Solaro RJ, Wolska BM. Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins. Circ Cardiovasc Genet. 2014 Apr 1;7(2):132-‐43
240. Liu Y, Lu X, Xiang FL, Poelmann RE, Gittenberger-‐de Groot AC, Robbins J, Feng Q. Nitric oxide synthase-‐3 deficiency results in hypoplastic coronary arteries and postnatal myocardial infarction. Eur Heart J. 2014 Apr;35(14):920-‐31
241. Sandri M, Robbins J. Proteotoxicity: An underappreciated pathology in cardiac disease. J Mol Cell Cardiol. 2014 Jun;71c:3-‐10
242. Wang X, Robbins J. Proteasomal and lysosomal protein degradation and heart disease. J Mol Cell Cardiol. 2014 Jun;71c:16-‐24
PUBLICATIONS IN PRESS 1. Dhandapany PS, Razzaque MA, Muthusami U, Kunnoth S, Edwards JJ, Riess I, Sheng J,
Hooda B, Mulero-‐Navarro S, Periyasamy G, Yokota T, Furutani M, Nishizawa T, Nakanishi T, Robbins J, Hajjar RJ, Lebeche D, Tartaglia M, Bahl A, Khullar M, Rathinavel A, Sadler KC, Matsuoka R, Thangaraj K, Gelb BD. RAF1 mutations in childhood-‐onset dilated cardiomyopathy. Nature Genetics.